On 10 July 2026, the Veterinary Medicines Directorate launched the VMD Industry Pharmacovigilance Reporting Service, a beta digital route for marketing authorisation holders to send safety data to the regulator. The move follows the VMD's public-facing Adverse Event Reporting Service, which went live on 20 May 2026 for animal owners, veterinary professionals and Suitably Qualified Persons. (gov.uk) The policy significance is not the creation of a new pharmacovigilance duty but a change in how existing duties can now be met. The VMD has presented the service as an optional reporting channel rather than an immediate mandatory replacement for earlier routes. (gov.uk)
According to the VMD's 10 July guidance, the service is for business use and brings several submission types into one platform. These include Benefit-Risk Submission Reports, Pharmacovigilance Sales Submissions, dose factor justification documents, signal notifications and XML adverse event files. (gov.uk) That consolidation matters because the same firms are often handling periodic benefit-risk work, sales data, signal management and case-based reporting through different internal teams. The VMD says the new system adds submission status tracking, exportable logs, in-system validation, digital forms for some reports and a built-in product dictionary to help users identify product groups and related information. (gov.uk)
The underlying compliance framework remains unchanged. In its pharmacovigilance guidance for Great Britain, the VMD states that marketing authorisation holders must continuously monitor the safety of their medicines, report adverse events within 30 days of awareness, notify signals suggesting a new risk or a change in benefit-risk balance within 30 days, send urgent signals within 1 to 3 days, and provide at least annual benefit-risk and sales data. The VMD links those expectations to the Veterinary Medicines Regulations 2013, as amended. (gov.uk) In that context, the beta service should be read as an administrative reform with compliance consequences. A single interface, validation checks and audit-style logs are likely to reduce avoidable filing errors and give firms a clearer record of what was submitted and when, although that is an inference from the functions described by the VMD rather than a formal regulatory claim. (gov.uk)
Access is not automatic. The VMD's published guidance says organisations must register before using the service and provide a named person, company details, licence information and, where relevant, an XML sender ID; the regulator may ask follow-up questions and will carry out checks to confirm that the business is entitled to use the service and that the applicant is a legitimate representative. (gov.uk) The same guidance also sets out an account-governance model that matters for outsourced compliance work. Consultants and agents cannot simply self-enrol unless they are already registered for the Veterinary Medicines Digital Service; instead, they must be invited into a company account, which means firms using external pharmacovigilance support may need to settle access permissions before reporting deadlines arise. (gov.uk)
The launch does not close off existing channels. The VMD says MA holders can continue to use the Veterinary Medicines Digital Service and VMDS adverse event reporting if they prefer secure messaging or manual routes, and the 10 July announcement describes the new offer as an optional beta. (gov.uk) There is also a clear separation between industry reporting and public reporting. The industry service is not for pet owners or the general public, who are directed to the separate adverse event portal launched on 20 May 2026; in practical terms, the VMD is now running parallel digital pathways for regulated firms and external reporters. (gov.uk)
For marketing authorisation holders, the immediate practical question is whether to begin piloting the beta now or wait for later development over the next year. The VMD has asked users to provide feedback through the service and says further functionality is already planned, which indicates that the operating model is still being refined in live use. (gov.uk) A proportionate next step would be to review internal reporting workflows against the new service design: identify who will act as the named person, decide which submissions will move into digital forms and which will remain file uploads, and check whether external agents need to be added to company accounts. For veterinary professionals and animal owners, the effect is more indirect, as their reporting route changed earlier in May; this July release mainly restructures how regulated companies send safety data to the VMD. (gov.uk)